The skies appeared almost apocalyptic over Crete (Picture: EPA)
Skies over the Greek island of Crete have turned blood red and flights arebeing diverted as a cloud of dust from the Sahara drifts over
But these trials haven’t been without speed bumps. Passengers of self-driving Waymo cars in San Francisco say that their trips have been cut short because of vandals or those opposed to robot cars.
The bus tracker tool is now live on Google Maps (Picture: Getty/Metro)
The pesky wait for a bus could be a little less uncertain after Google Maps launched a new tracking feature.
BEIJING,Dec. 9,2024-- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM),a healthcare provider specialized in cancer treatment,research,educa
SHANGHAI and HONG KONG,Dec. 10,2024-- Antengene Corporation Limited ("Antengene",SEHK: 6996.HK),a leading innovative,commercial-stage global biopharmaceutical company dedicated to discoveri
A new commercial arrangement between Geotab and Logmaster combines Geotab\'s world-leading telematics solutions with Logmaster\'s best in class compliance technology in Australia
BEIJING,Dec. 5,2024-- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"),the first U.S.-listed EV charging service company in China,today announced a new partnership wit
2025 is set to be a strong year for WeTV with bigger,better,and more entertaining Southeast Asian offerings,including an all-new season of CHUANG ASIA,a slew of WeTV Originals in Thailand and Indonesi
NANJING,China,Dec. 5,2024-- This is a news report from JICC: China\'s renowned ancient paths are not merely historical records etched into the land—they are living embodiments of evolving modern civi
SINGAPORE,Dec. 6,2024-- IMAGINE AI is the largest calendar event in Singapore that brings together the brightest minds in healthcare and artificial intelligence to explore the transformative potenti
HONG KONG,Dec. 4,2024-- Akeso,Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective,open-label,single-arm,multi-center phase Ib/II clinical study (AK10
